180 Life Sciences Corp. Reports Board and Compensation Changes
Ticker: FRMM · Form: 8-K · Filed: Dec 18, 2024 · CIK: 1690080
Sentiment: neutral
Topics: management-change, board-of-directors, executive-compensation
Related Tickers: ATNF
TL;DR
180 Life Sciences just swapped some board members and updated exec pay. Big changes ahead?
AI Summary
180 Life Sciences Corp. announced on December 16, 2024, changes in its board of directors and executive compensation arrangements. The filing details the departure of certain directors and the election of new ones, alongside updates to the compensatory arrangements for its officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance, impacting investor confidence.
Risk Assessment
Risk Level: medium — Board and executive changes can introduce uncertainty regarding future strategy and operational direction.
Key Players & Entities
- 180 Life Sciences Corp. (company) — Registrant
- December 16, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
FAQ
Who are the new directors elected to the board of 180 Life Sciences Corp.?
The filing indicates the election of new directors but does not name them in the provided text.
Which directors have departed from 180 Life Sciences Corp.?
The filing states the departure of certain officers and directors but does not specify their names in the provided text.
What specific changes were made to the compensatory arrangements of officers?
The filing mentions updates to compensatory arrangements but does not detail the specifics in the provided text.
What is the exact date of the earliest event reported in this 8-K filing?
The earliest event reported is dated December 16, 2024.
Under which section of the Securities Exchange Act of 1934 is this 8-K report filed?
This report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 617 words · 2 min read · ~2 pages · Grade level 12.6 · Accepted 2024-12-18 16:15:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share ATNF The NASDAQ Stock Mar
Filing Documents
- ea0225237-8k_180life.htm (8-K) — 29KB
- 0001213900-24-110152.txt ( ) — 242KB
- atnf-20241216.xsd (EX-101.SCH) — 4KB
- atnf-20241216_def.xml (EX-101.DEF) — 26KB
- atnf-20241216_lab.xml (EX-101.LAB) — 36KB
- atnf-20241216_pre.xml (EX-101.PRE) — 25KB
- ea0225237-8k_180life_htm.xml (XML) — 6KB
02 Departure of Directors or Certain Officers;
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On December 16, 2024, Mr. Omar Jimenez, the Chief Financial Officer (principal financial/accounting officer) and Secretary of 180 Life Sciences Corp. (the " Company ", " we " and " us "), tendered his resignation to the board of directors of the Company (the " Board "), effective immediately. Mr. Jimenez's resignation was not the result of a disagreement with the Company on any matter relating to the Company's operations, policies or practices. As a result of Mr. Jimenez's resignation, current Interim Chief Executive Officer, Blair Jordan, assumed the role of principal financial/accounting officer of the Company, effective as of the date of Mr. Jimenez's resignation, on an interim basis, until such time as a replacement is named. Biographical and other information regarding Mr. Jordan is set forth in the Company's proxy statement, filed with the Securities and Exchange Commission on November 12, 2024, under the section " Information About Our Executive Officers and Directors—Director Nominees ", and such information is incorporated by reference herein. There are no arrangements or understandings between Mr. Jordan and any other person requiring disclosure under Item 401(b) of Regulation S-K and no transactions with related persons requiring disclosure under Item 404(a) of Regulation S-K, except as disclosed in the proxy statement. Mr. Jordan will not receive any additional compensation in connection with assuming the responsibilities of the principal accounting/financial officer of the Company on an interim basis.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 18, 2024 180 LIFE SCIENCES CORP. By: /s/ Blair Jordan Name: Blair Jordan Title: Interim Chief Executive Officer